AI assistant
Evotec SE — Regulatory Filings 2016
Jan 7, 2016
151_rns_2016-01-07_5c7bd465-df63-41ce-aaa7-547d5e8d093a.html
Regulatory Filings
Open in viewerOpens in your device viewer
News Details
Corporate | 7 January 2016 07:30
Evotec and UCB sign multi-year sample management agreement
DGAP-News: Evotec AG / Key word(s): Alliance
2016-01-07 / 07:30
The issuer is solely responsible for the content of this announcement.
Hamburg, Germany - 07 January 2016: Evotec AG (Frankfurt Stock Exchange:
EVT, TecDAX, ISIN: DE0005664809) today announced an EVT Execute
collaboration aimed at providing a complete solution to UCB's global sample
management requirements.
Under the terms of the agreement, Evotec will manage UCB's compound
collection out of its state-of-the-art sample management facility in
Toulouse, France. The agreement covers an initial period of five years.
Dr Mario Polywka, Chief Operating Officer of Evotec, stated: "We are
delighted to expand our long standing and successful relationship with UCB
through this collaboration designed to provide sample management
infrastructure, logistics and expertise to support their drug discovery
efforts. This collaboration will use the first-class team and best-in-class
infrastructure from our Toulouse site which was acquired in April 2015."
Dr Neil Weir, Senior Vice President of Discovery at UCB, commented: "With
Evotec's proven track record in compound management coupled with global
operations and an outstanding team and facility in Toulouse, we are
confident of the quality and scalability of the services our internal and
external discovery teams will receive."
No financial details were disclosed.
ABOUT UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company
focused on the discovery and development of innovative medicines and
solutions to transform the lives of people living with severe diseases of
the immune system or of the central nervous system. With more than 8500
people in approximately 40 countries, the company generated revenue of EUR
3.3 billion in 2014. UCB is listed on Euronext Brussels (symbol: UCB).
Follow us on Twitter: @UCB_news
ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies, academics, patient advocacy
groups and venture capitalists. We operate worldwide providing the highest
quality stand-alone and integrated drug discovery solutions, covering all
activities from target-to-clinic. The Company has established a unique
position by assembling top-class scientific experts and integrating
state-of-the-art technologies as well as substantial experience and
expertise in key therapeutic areas including neuroscience, pain, metabolic
diseases as well as oncology, inflammation and infectious diseases. Evotec
has long-term discovery alliances with partners including Bayer, Boehringer
Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca,
Roche and UCB. In addition, the Company has existing development
partnerships and product candidates both in clinical and pre-clinical
development. These include partnerships with Boehringer Ingelheim and
MedImmune in the field of diabetes, with Janssen Pharmaceuticals in the
field of depression and with Roche in the field of Alzheimer's disease. For
additional information please go to www.evotec.com.
FORWARD LOOKING STATEMENTS - Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent
the judgement of Evotec as of the date of this press release. Such
forward-looking statements are neither promises nor guarantees, but are
subject to a variety of risks and uncertainties, many of which are beyond
our control, and which could cause actual results to differ materially from
those contemplated in these forward-looking statements. We expressly
disclaim any obligation or undertaking to release publicly any updates or
revisions to any such statements to reflect any change in our expectations
or any change in events, conditions or circumstances on which any such
statement is based.
Contact Evotec AG:
Gabriele Hansen, VP Corporate Communications & Investor Relations, Phone:
+49.(0)40.56081-255, [email protected]
2016-01-07 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: [email protected]
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart
End of News DGAP News Service